These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

721 related items for PubMed ID: 7542397

  • 1. Prostate cancer. Mortality and morbidity after non-curative treatment with aspects on diagnosis and treatment.
    Aus G.
    Scand J Urol Nephrol Suppl; 1994; 167():1-41. PubMed ID: 7542397
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer.
    Zincke H, Lau W, Bergstralh E, Blute ML.
    J Urol; 2001 Dec; 166(6):2208-15. PubMed ID: 11696737
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Volume-adjusted prostate-specific antigen (PSA) variables in detecting impalpable prostate cancer in men with PSA levels of 2-4 ng/mL: transabdominal measurement makes a significant contribution.
    Kobayashi T, Kawahara T, Nishizawa K, Ogura K, Mitsumori K, Ide Y.
    BJU Int; 2005 Jun; 95(9):1245-8. PubMed ID: 15892809
    [Abstract] [Full Text] [Related]

  • 8. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C, Kestin LL, Weed DW, Krauss D, Vicini FA, Martinez AA.
    Int J Radiat Oncol Biol Phys; 2005 Mar 01; 61(3):714-24. PubMed ID: 15708249
    [Abstract] [Full Text] [Related]

  • 9. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P, Katcher J, Levin H, Zippe C, Suh J, Macklis R, Klein E.
    Cancer J Sci Am; 1997 Mar 01; 3(2):78-87. PubMed ID: 9099457
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: preliminary results.
    Gelet A, Chapelon JY, Bouvier R, Pangaud C, Lasne Y.
    J Urol; 1999 Jan 01; 161(1):156-62. PubMed ID: 10037389
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Rationale for using serum prostate-specific antigen (PSA) level and PSA density (PSAD) to detect prostatic malignancy in a country with low prostate cancer incidence.
    Rahardjo D, Kamil ST, Pakasi LS.
    Gan To Kagaku Ryoho; 2000 May 01; 27 Suppl 2():563-70. PubMed ID: 10895211
    [Abstract] [Full Text] [Related]

  • 16. Comparison of 6- and 12-core prostate biopsy in Taiwanese men: impact of total prostate-specific antigen, prostate-specific antigen density and prostate volume on prostate cancer detection.
    Chiang IN, Chang SJ, Pu YS, Huang KH, Yu HJ, Huang CY.
    Urol Int; 2009 May 01; 82(3):270-5. PubMed ID: 19440012
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
    Leibovici D, Spiess PE, Agarwal PK, Tu SM, Pettaway CA, Hitzhusen K, Millikan RE, Pisters LL.
    Cancer; 2007 Jan 15; 109(2):198-204. PubMed ID: 17171704
    [Abstract] [Full Text] [Related]

  • 20. [Prostate-specific antigen in the diagnosis of organ-confined treatable prostate carcinoma].
    Recker F.
    Schweiz Med Wochenschr; 1996 Nov 02; 126(44):1881-90. PubMed ID: 8984601
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.